Estudio en fase II de Nevelbine + Cisplatino + etopósido en el tratamiento de cáncer de pulmón no células pequeñas inoperable
40 patients with advanced non-small cell luna cancer lot previously treated were included in a study at puase II with vinorelbine 20 mg/Sq.m days 1 and 8, etoposide 60 mg/sq.m days 1-3 and cisplatin 75 mg/sq.m day 1 1 each 28 days for 6 cycles. There were 31 iiien and 9 women, being the average age...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
1995
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/40661 |
| Aporte de: |
| Sumario: | 40 patients with advanced non-small cell luna cancer lot previously treated were included in a study at puase II with vinorelbine 20 mg/Sq.m days 1 and 8, etoposide 60 mg/sq.m days 1-3 and cisplatin 75 mg/sq.m day 1 1 each 28 days for 6 cycles.
There were 31 iiien and 9 women, being the average age of 54 years, with "performance Status" grade 0-2. Al! of theni could be cvaluated for toxicity and 31 for responsiveness. 10 patients were 11 stage ilib and 21 at stage W. 42% of objective responses 'ere obtained and an overa!] survival of 9 iionths, which justifies fiirther studies. |
|---|